The effect of targeted treatment on people with patellofemoral pain: a pragmatic, randomised controlled feasibility study

Table 5 Clinical outcomes. Mean (SD) unless otherwise stated

Outcome	Group	Baseline (SD)	Post treatment (SD)	Mean difference (baseline –post) (SD)	Confidence intervals (95%)	Mean difference (MT-Control) (95% CI)	ES (d) (MT- control)
AKPS	MT	75.08 (10.09)	80.31 (8.66)	−5.23 (10.17)	−11.37, 0.91	−6.41 (−14.23, 1.41)	0.70
AKPS	UC	73.64 (12.23)	72.45 (16.94)	1.18 (7.91)	−4.13, 6.49	−6.41 (−14.23, 1.41)	0.70
Worst NRS	MT	4.85 (1.68)	4.62 (2.10)	0.23 (2.05)	−1.01, 1.47	−0.41 (−1.93, 1.12)	0.23
Worst NRS	UC	5.27 (2.33)	4.64 (2.16)	0.64 (1.43)	−0.33, 1.59	−0.41 (−1.93, 1.12)	0.23
Average NRS	MT	3.08 (1.38)	2.46 (1.33)	0.62 (1.33)	−0.19, 1.42	−0.02 (−1.01, 0.96)	0.02
Average NRS	UC	3.73 (2.19)	3.09 (1.87)	0.64 (0.92)	0.02, 2.28	−0.02 (−1.01, 0.96)	0.02
GROC	MT		61.5% (8/13)
GROC	UC		9.1% (1/11)

AKP anterior knee pain scale, MT matched treatment, UC usual care group, NRS numerical rating scale, GROC global rating of change scale, ES effect size

ISSN: 1471-2474